Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.

被引：0
|
作者：
Ulahannan, Susanna Varkey
Johnson, Melissa Lynne
Weiss, Mia C.
Vandross, Andrae L.
Vidal-Cardenas, Sofia Luz
Syed, Mustafa
Tolcher, Anthony W.
机构：
[1] Univ Okahoma Hlth Sci Ctr, Oklahoma City, OK USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] NEXT Oncol, Austin, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
283-2494-5577-2829-12292; 613-135-244-3829-325; 3282-3306-2666-3910; 283-324; 613-4678-146-3542; 261-436; 3282-4644-9184; 6; 3; 2;
D O I：
10.1200/JCO.2024.42.4_suppl.TPS237
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS237 / TPS237
页数：1
相关论文
共 28 条
  • [21] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Yu, Evan Y.
    Kolinsky, Michael P.
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Appleman, Leonard J.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    Bogemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Linch, Mark
    Sridhar, Srikala
    Conter, Henry J.
    Laguerre, Brigitte
    Massard, Christophe
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian H.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
  • [22] Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
    Subbiah, V.
    Falchook, G.
    Davis, A. A.
    Wang, J. S.
    de Miguel, M.
    Santoro, A.
    Maur, M.
    Aljumaily, R.
    Boni, V.
    de Speville, B. Doger
    Sun, Y.
    Du, Y.
    Lakshmikanthan, S.
    Bedse, G.
    Ward, A.
    Zweidler-McKay, P.
    Gandhi, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S72 - S73
  • [23] Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study (vol 83, pg 15, 2023)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz, Jose A.
    Oudard, Stephane
    Massard, Christophe
    Heinzelbecker, Julia
    Nordquist, Luke T.
    Carles, Joan
    Kolinsky, Michael P.
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Qiu, Ping
    Poehlein, Christian H.
    Schloss, Charles
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2023, 83 (03) : E87 - E87
  • [24] Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.
    Jayaram, Anuradha
    Nowakowska, Karolina
    Mateo, Joaquin
    Rodrigues, Daniel Nava
    Riisnaes, Ruth
    Zukiwski, Alexander
    Proniuk, Stefan
    Bexon, Alice Susannah
    Bisaha, Joseph
    Bianchini, Diletta
    Zafeiriou, Zafeiris
    Lopez, Raquel Perez
    Tunariu, Nina
    De Bono, Johann Sebastian
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study
    Wu, Jiong
    Zhang, Jian
    Du, Yiqun
    Zou, Wen
    Ding, Muran
    Yang, Hui
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin
    Zhu, Yi
    CANCER RESEARCH, 2024, 84 (09)
  • [26] A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
    Spira, Alexander I.
    Lee, Elizabeth Katherine
    O'Cearbhaill, Roisin Eilish
    LoRusso, Patricia
    Falchook, Gerald Steven
    Patel, Manish R.
    Richardson, Debra L.
    Lu, Nicole Covino Wei
    Marreddy, Priya
    Farrington, Daphne L.
    Wheler, Jennifer J.
    Slosberg, Eric Daniel
    Subbiah, Vivek
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
    Bendell, Johanna
    Ulahannan, Susanna V.
    Chu, Quincy
    Patel, Manish
    George, Ben
    Landsberg, Renee
    Elgadi, Mabrouk
    Duffy, Christine
    Graeser, Ralph
    Tang, Wenbo
    Merger, Michael
    Ge, Miaomiao
    Johnson, Melissa
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [28] BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
    Song, Erwei
    Yao, Herui
    Sun, Meili
    Zong, Hong
    Lin, Rongbo
    Zou, Wen
    Ding, Muran
    Yu, Jing
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin
    Zhu, Yi
    CANCER RESEARCH, 2024, 84 (09)
123